Bath & Body Works printed its Q1 results on May 27 and the stock has snapped back — up 10% on the week to $17.73 — but the short side has barely flinched, and the analyst community spent the days before the print cutting targets rather than building conviction.
The short position tells the story of a market that isn't convinced the bounce has legs. Short interest as a percentage of the free float has eased marginally from the ~8.3% level flagged in last week's note, but only to 7.75% — still well above the 7.5% range that prevailed through late April. The month-on-month change is up nearly 12%, confirming that the build since early May was real and persistent. Borrow conditions remain completely untested — cost to borrow is a negligible 0.35%, and availability is an enormous 2,509% of short interest, down sharply from above 3,900% last week but still so loose that any new short faces zero friction entering the position. The week's availability decline is worth noting but does not signal any tightening pressure; the pool of shares to borrow remains vast relative to what's actually borrowed. Options positioning is neutral to slightly constructive: the put/call ratio of 0.77 is fractionally below its 20-day average of 0.79, and the z-score of -0.20 places it squarely in the middle of recent ranges. There is no defensive hedging signal in the options market worth highlighting.
The Street's posture heading into this week's earnings was clearly one of managed expectations, not enthusiasm. Three firms cut targets in the ten days before the print. UBS trimmed to $19 from $22, keeping a Neutral rating. TD Cowen lowered to $20 from $26 while maintaining Buy — a target cut of that magnitude from a bull is a meaningful reset of upside expectations. Piper Sandler stepped in with a fresh Neutral at $20, stepping down from a prior Overweight. The mean price target now sits at $26.54, which against a $17.73 close implies roughly 50% upside on paper — but that figure is anchored by stale targets set before the recent leg down, and the recent direction of travel is uniformly lower. The EV/EBITDA multiple of 6.2x and a PE of 6.5x look cheap in isolation. The EV/EBIT factor score ranks at the 95th percentile, meaning on an earnings-yield basis this stock screens as one of the most attractively valued in the universe. Bears would argue the cheapness is deserved: 77% of sales through physical stores, 96% North American revenue concentration, and a body-care category that has been losing ground.
On the institutional side, Fidelity's FMR added nearly 3.9 million shares in the April reporting period, making it the largest holder at just over 10% of shares outstanding. D. E. Shaw added 3.7 million shares in Q1, and Point72 built a new position of 1.9 million shares — three active managers moving meaningfully in the same direction. That institutional accumulation at lower prices is the clearest structural bull signal in the data, though it predates the stock's post-earnings move this week.
Insider activity has been a net seller in recent months. The CEO sold 7,334 shares at $17.09 on May 15, and the CFO sold 10,782 shares at $19.50 in March. These are small transactions by value, but the direction from the C-suite is out rather than in — a contrast with the November cluster of board-level buying below $16, which now sits at a profit. Net insider value over the past 90 days is a modest positive $525,000, but that's driven entirely by those November board purchases; the more recent exec activity has been one-directional selling.
With Q1 now reported, the next event on the calendar is June 11. Whether the post-earnings bounce proves durable — or whether the persistent short position and analyst target resets anchor the stock — is the question the market will be wrestling with between now and that date.
See the live data behind this article on ORTEX.
Open BBWI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
